Table 1.
Demographic Characteristics of the Study Participants
| Variable | Patients (n=80) |
|---|---|
| Age (years) | |
| <30 | 26 (32.5%) |
| 30–50 | 45 (56.2%) |
| >50 | 9 (11.3%) |
| Gender | |
| Male | 72 (90%) |
| Female | 8 (10%) |
| HIV transmission route | |
| Homosexual | 67 (83.8%) |
| Heterosexual | 11 (13.8%) |
| Others | 2 (2.5%) |
| CD4 count, cells/µL, at baseline, median (25th–75th) | 263 (62–402) |
| HIV-1 RNA copies/mL at baseline, median (25th–75th) | 297,107 (43,652–424,165) |
| Plasma viral load at LLV, copies/mL | |
| 50–99 | 43 (53.7%) |
| 100–199 | 14 (17.5%) |
| 200–399 | 12 (15%) |
| 400–999 | 11 (13.8%) |
| ART regimen | |
| 3TC+TDF+EFV | 63 (78.8%) |
| 3TC+TDF+LPV/r | 5 (6.3%) |
| TAF+EVG/c/FTC | 3 (3.8%) |
| AZT+3TC+EFV | 2 (2.5%) |
| 3TC+TDF+DTG | 2 (2.5%) |
| Others | 5 (6.3%) |
| Type of LLV | |
| iLLV | 50 (62.5%) |
| pLLV | 30 (37.5%) |
Abbreviations: 3TC, lamivudine; TDF, tenofovir; EFV, efavirenz; LPV/r, lopinavir/ritonavir; TAF, tenofovir alafenamide; EVG/c/FTC, elvitegravir; FTC, emtricitabine; AZT, zidovudine; DTG, dolutegravir; LLV, low-level viremia; iLLV, intermittent low-level viremia; pLLV, persistent low-level viremia.